Printer Friendly

Alnylam licenses intellectual property in RNA interference.

Alnylam Pharmaceuticals, Inc. (Cambridge, MA) has signed a licensing agreement with Stanford University (Stanford, CA) for intellectual property related to the method for inducing gene silencing through RNAi in adult mammals. The licensing of this additional intellectual property expands Alnylam's leadership position in the fundamental patents, technology and know-how that underlie the discovery, development and commercialization of RNAi-based therapeutics.

Alnylam executed a co-exclusive therapeutic license from Stanford University for the RNA interference patent application and related technology which is based on the research of Dr. Mark Kay, Dr. Anton McCaffrey and colleagues at the Stanford University School of Medicine. This intellectual property encompasses the demonstration that delivery of synthetic small interfering RNA molecules to an adult mammal can induce in vivo silencing of a specific target gene, thereby a basis for the systemic administration of RNAi-based therapies in mammals.

"The addition of this intellectual property from Stanford, when combined with our existing portfolio of the fundamental patents in the field of RNAi, further strengthens Alnylam's clear leadership in worldwide intellectual property for the development of RNAi-based therapeutics," said Dr. John Maraganore, president and CEO of Alnylam. "We continue to fortify our intellectual property foundation in RNAi that uniquely positions us to develop and commercialize a new class of medicines."

Alnylam is a leading company in the emerging field of RNA interference (RNAi) whose vision is to Harness a Revolution in Biology for Human Health. Growing from its foundation as the world's first company focused on RNAi-based therapeutics, the company is built around the leading capabilities of its two operating units, Alnylam Pharmaceuticals, and Ribopharma (Kulmbach, Germany). Over the last several years, RNAi has been identified as a fundamental cellular mechanism for gene silencing. The company's leadership in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how that underlie the commercialization of RNAi-based therapeutics. The company's focus is to discover, develop, and commercialize therapeutic products based on RNAi for a broad range of therapeutic indications including viral, oncologic, metabolic, CNS and autoimmune diseases. The company's mission is to lead research in the field of RNAi, to build the leading pipeline of RNAi-based therapeutics, and to emerge as business leaders.

Alnylam Pharmaceuticals, Inc.

COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:to Stanford University
Comment:Alnylam licenses intellectual property in RNA interference.(to Stanford University)
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Sep 1, 2003
Previous Article:Generex Biotechnology announces grant of European patent for aerosol delivery.
Next Article:Cambridge Antibody and Dyax amend antibody product agreement.

Related Articles
Alnylam licenses RNA interference patents.
Alnylam licenses RNA interference patents.
Alnylam grants RNAx license to key patent in RNA interference.
Alnylam licenses gene silencing technology from Cold Spring Harbor.
Alnylam and Cenix enter into RNAi research service agreement.
Alnylam licenses gene silencing technology from Cold Spring Harbor.
Alnylam grants Nastech a License to develop RNAi therapeutics against TNF-alpha.
Isis expects to earn initial payments of nearly $4 million from Alnylam's recent RNAi collaboration.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters